MEK inhibitors against MET-amplified non-small cell lung cancer

MEK inhibitors against MET-amplified non-small cell lung cancer

Several receptor tyrosine kinases (RTKs) including EGFR, ALK, and MET have been identified as therapeutic targets in non-small cell lung cancer (NSCLC). Among the downstream pathways of RTKs, the MAPK pathway is particularly important for cancer cell proliferation, differentiation, and survival. In...

Full description

Bibliographic Details
Main Authors: Chiba, Masato, Togashi, Yosuke, Tomida, Shuta, Mizuuchi, Hiroshi, Nakamura, Yu, Banno, Eri, Hayashi, Hidetoshi, Terashima, Masato, De Velasco, Marco A., Sakai, Kazuko, Fujita, Yoshihiko, Mitsudomi, Tetsuya, Nishio, Kazuto
Format: Online
Language:English
Published: D.A. Spandidos 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118002/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118002/

Similar Items